1 July 2022
Current Oncology | Collaboration with the Canadian Leukemia Study Group (CLSG)
You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.
Original Submission Date Received: .
In February 2022, Current Oncology (ISSN: 1718-7729) established a new collaboration with the Canadian Leukemia Study Group. As part of this collaboration, all affiliated CLSG members will enjoy a discount on Article Processing Charges (APC) when submitting articles to Current Oncology.
CLSG is a collective of Canadians striving for cutting-edge acute leukemia care. Every Canadian with leukemia deserves access to world-class therapy, including the latest drug advancements, leading-edge research, diagnostic technologies, and trials. That is why CLSG strives to connect Canadians with every resource possible. CLSG’s goal is to improve acute leukemia care in Canada by advancing a world-class standard of care for all Canadians, and by facilitating the ability of those who treat leukemia across the country to deliver optimal quality care equitably.
Current Oncology represents a multidisciplinary medium which invites healthcare workers in the field of cancer therapy to report upon and review progress in the management of this disease. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice and have clear potential for application to the current or future practice of cancer medicine. Current Oncology is covered by leading indexing services, including the Science Citation Index Expanded (Web of Science), Scopus, PubMed, MEDLINE, PMC, Embase, and many other databases.
Current Oncology looks forward to a very fruitful collaboration with CLSG.